botulinum antitoxin
Jump to navigation
Jump to search
Indications
- treatment of naturally occurring noninfant botulism
Mechanism of action
- equine-derived antibody to the 7 known botulinum toxin types (A-G)
- composed of <2% intact immunoglobulin G (IgG) & >=90% Fab & F(ab')2 immunoglobulin fragments
- Fab & F(ab')2 fragments are cleared from circulation more rapidly than intact IgG1)
- repeat HBAT dosing might be indicated for some wound or intestinal colonization patients if in situ botulinum toxin production continues after clearance of antitoxin
- does NOT reverse existent paralysis[3]
Notes
- available only from CDC
More general terms
Additional terms
References
- ↑ Centers for Disease Control and Prevention (CDC) Investigational Heptavalent Botulinum Antitoxin (HBAT) to Replace Licensed Botulinum Antitoxin AB and Investigational Botulinum Antitoxin E Morbidity and Mortality Weekly Report (MMWR) 2010, 59(10);299 http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5910a4.htm
- ↑ FDA News Release: March 22, 2013 FDA approves first Botulism Antitoxin for use in neutralizing all seven known botulinum nerve toxin serotypes. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm345128.htm
- ↑ 3.0 3.1 Medical Knowledge Self Assessment Program (MKSAP) 18, American College of Physicians, Philadelphia 2018
- ↑ CDC's botulism treatment program http://www.bt.cdc.gov/agent/botulism